Edition:
United States

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

9.55USD
23 Feb 2018
Change (% chg)

$0.40 (+4.37%)
Prev Close
$9.15
Open
$9.25
Day's High
$9.60
Day's Low
$9.10
Volume
72,931
Avg. Vol
144,285
52-wk High
$26.55
52-wk Low
$8.07

Select another date:

Fri, Jan 5 2018

BRIEF-Coherus Biosciences Says ‍Had Cash And Cash Equivalents Of About $126.9 Million

* COHERUS BIOSCIENCES SAYS ‍HAD CASH AND CASH EQUIVALENTS OF ABOUT $126.9 MILLION AS OF DEC 31 - SEC FILING​ Source text : (http://bit.ly/2qqVZLs) Further company coverage:

BRIEF-Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint

* COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM

BRIEF-Temasek Holdings (Private) Ltd ups share stake in Mastercard, Visa and Monsanto

* Temasek Holdings (Private) Ltd ups share stake in Mastercard to 923,068 class a shares from 267,006 class a shares

BRIEF-Coherus Biosciences Q3 loss per share $1.09

* Coherus Biosciences reports third quarter 2017 operating and financial results

BRIEF-Coherus Biosciences files for offering of upto 6.56 million shares of common stock by the selling stockholder‍​

* Coherus Biosciences Inc - Files for offering of upto 6.56 million shares of common stock by the selling stockholder‍​ - SEC filing Source text: (http://bit.ly/2xYarNR) Further company coverage:

BRIEF-‍Temasek Holdings reports 11.32 pct passive stake in Coherus Biosciences

* ‍Temasek Holdings (private) Ltd​ reports 11.32 pct passive stake in Coherus Biosciences Inc as of Aug 24 - sec filing Source text - http://bit.ly/2esXsfi Further company coverage:

BRIEF-Coherus Biosciences announces positive topline results for study for Humira biosimilar vs European marketed Humira in healthy subjects

* Coherus Biosciences announces positive topline results for clinical pharmacokinetic bioequivalence study for CHS-1420 (Humira® biosimilar candidate) versus European marketed Humira in healthy subjects

Select another date: